Guohong Han

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.3K citations · Full text

Hepatology, Medicine, Randomised Phase 3 +11

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukui Qin, Philippe Merle et al. · The Lancet · 2016 · 3.6K citations · Full text

Hepatology, Medicine, Sorafenib Treatment +8

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Jian Zhou, Hui‐Chuan Sun, Zheng Wang et al. · Liver Cancer · 2020 · 813 citations · Full text

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial

Riccardo Lencioni, Josep M. Llovet, Guohong Han et al. · Journal of Hepatology · 2016 · 680 citations · Full text

Doxorubicin-eluting Beads, Intermediate Stage Hcc, Pharmacology +8

The role of hepatic resection in the treatment of hepatocellular cancer

Sasan Roayaie, Ghalib Jibara, Parissa Tabrizian et al. · Hepatology · 2015 · 402 citations

Surgical Oncology, Gastroenterology, Multimodality +24